scholarly journals Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study

2020 ◽  
Vol 129 ◽  
pp. 97-106 ◽  
Author(s):  
Akihito Kawazoe ◽  
Kensei Yamaguchi ◽  
Hisateru Yasui ◽  
Yuji Negoro ◽  
Mizutomo Azuma ◽  
...  
Keyword(s):  
Gastroesophageal Junction ◽  
Line Treatment ◽  
First Line ◽  
Safety And Efficacy ◽  
Gastroesophageal Junction Cancer ◽  
First Line Treatment

Efficacy and safety of toripalimab combination with SOX regimen as a first-line treatment in patients with unresectable locally advanced or recurrent/metastatic gastric/gastroesophageal junction cancer: Preliminary data from a single-armed, exploratory study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16015-e16015
Author(s):  
Xiaolin Lin ◽  
Qing Xia ◽  
Ting Han ◽  
Meng Zhuo ◽  
Haiyan Yang ◽  
...  
Keyword(s):  
Disease Control ◽  
Gastroesophageal Junction ◽  
Objective Response ◽  
Locally Advanced ◽  
Disease Control Rate ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
First Line ◽  
Gastroesophageal Junction Cancer ◽  
First Line Treatment

e16015 Background: Gastric cancer (GC) is one of the most common malignancies of the digestive system with a poor prognosis and limited treatment option. Currently immunotherapy is approved for the third-line treatment of GC, but there are limited data on first-line treatment. Therefore, this study will further explore the efficacy and safety of the domestic PD-1 antibody toripalimab combined with S-1 plus oxaliplatin (SOX) regimen as the first-line treatment of unresectable locally advanced or recurrent/metastatic gastric/gastroesophageal junction cancer. Methods: A prospective, single-armed, exploratory, investigated initiated trial explores the efficacy and safety of toripalimab combined with SOX regimen as first-line treatment of unresectable locally advanced or recurrent/metastatic gastric/gastroesophageal junction cancer. The primary objectives are objective response rate (ORR). Secondary objectives include disease control rate (DCR), DOR, PFS, and OS. The dosage regimen is: Toripalimab, 240mg D1; oxaliplatin, 130mg/m2, D1 ; S-1, 40mg/m2, bid oral D1-14 days, every 21 days as a cycle and plan 6 cycles of treatment. Tumor responses were assessed radiologically every two cycles. Major eligibility requirements include: unresectable advanced, recurrent or metastatic gastric/gastroesophageal junction cancer with diagnoses confirmed histologically or cytologically, age 18 and 80 years, first-line treatment, at least one measurable lesion according to RECIST 1.1, ECOG 0-1, adequate organ function and HER-2 negative. Results: So far, 17 of planned 20 patients have been enrolled. 14 patients completed 2 cycles of treatment, the ORR rate was 57% (8/14) and the disease control rate (DCR) was 93% (13/14). 10 patients completed 4 cycles of treatment, the ORR rate was 60% (6/10) and the disease control rate (DCR) was 90% (9/10). 7 patients completed 6 cycles of treatment, the ORR rate was 43% (3/7) and the disease control rate (DCR) was 57% (4/7). Common adverse reactions during treatment in 17 patients included rash 17.6% (3/17), diarrhea 41.2% (7/17), hypothyroidism 11.8% (2/17), elevated amylase 35.3% (6/17), decreased platelets 41.2% (7/17), mostly grade I-II. Conclusions: Toripalimab combination with SOX regimen as a first-line treatment demonstrated promising anti-tumor activity in unresectable locally advanced or recurrent/metastatic gastric/gastroesophageal junction cancer patients with a good ORR and controllable safety. Clinical trial information: NCT04202484.

A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients

Chemotherapy ◽  
2012 ◽  
Vol 58 (5) ◽  
pp. 411-418 ◽  
Author(s):  
Yung-Sung Yeh ◽  
Hsiang-Lin Tsai ◽  
Cheng-Jen Ma ◽  
Deng-Chyang Wu ◽  
Chien-Yu Lu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Line Treatment ◽  
First Line ◽  
Safety And Efficacy ◽  
Recurrent Gastric Cancer ◽  
Gastric Cancer Patients ◽  
First Line Treatment

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

2018 ◽  
Vol 36 (4) ◽  
pp. 674-682 ◽  
Author(s):  
Arthur Lui ◽  
Karen Mulder ◽  
Christine Brezden-Masley ◽  
Michael Vickers ◽  
Jose Monzon ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Gastroesophageal Junction ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Open Label Phase ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document